Reuters logo
BRIEF-Acceleron and Celgene announce updated results from ongoing phase 2 studies of Luspatercept in Myelodysplastic Syndromes at 58th annual meeting of American Society of Hematology
December 7, 2016 / 9:36 PM / a year ago

BRIEF-Acceleron and Celgene announce updated results from ongoing phase 2 studies of Luspatercept in Myelodysplastic Syndromes at 58th annual meeting of American Society of Hematology

Dec 7 (Reuters) - Celgene Corp

* Acceleron and Celgene announce updated results from ongoing phase 2 studies of Luspatercept in Myelodysplastic Syndromes at 58th annual meeting of American Society of Hematology

* Acceleron Pharma Inc says preliminary data in esa naïve and rs- patients are encouraging

* Acceleron Pharma - Preliminary results show that treatment with investigational drug Luspatercept increases hemoglobin

* Acceleron Pharma-Results also show treatment with investigational drug achieves durable transfusion independence in patients with lower risk Myelodysplastic Syndromes Source text: [bit.ly/2h7aVpY] Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below